Search
A prostate-specific antigen (PSA) test taken for the first time between the ages of 44 and 50 can predict the likelihood that a man will die from prostate cancer over the next 25 to 30 years, according to researchers at Memorial Sloan Kettering Cancer Center.
Pituitary adenomas continue to grow in a small subset of patients despite treatment with standard surgery and radiotherapy. Recognizing the significant unmet needs in this cohort, we recently published a review of the latest treatment options.
Several Memorial Sloan Kettering investigators are focused on the study of bacteria, which can teach us much about human health, and about cancer in particular.
Degrees were presented and awards were given at the 38th annual ceremony held on May 18.
By blocking a source of inflammation in the skin, it may be possible to prevent or treat lymphedema, a common and debilitating cancer complication.
Since its inception at MSK 10 years ago, the Immigrant Health and Cancer Disparities (IHCD) Service has made significant progress in addressing barriers to access to cancer treatment and other healthcare for underserved communities across New York City and beyond.
Dr. Diane Reidy-Lagunes discusses cannabis and cancer with MSK’s Director of Pediatric Integrated Medicine, Dr. Nirupa Raghunathan, and cancer survivor and winner of TV’s “Survivor: Africa”, Ethan Zohn.
Learn how a new treatment approach using high-dose radiation has given hope to people with inoperable tumors.
Meet Dario Cortes, who was treated for rectal cancer at Memorial Sloan Kettering and is now back to doing the activities he loves.
Conozca a Dario Cortes, que recibió tratamiento para el cáncer rectal en el Memorial Sloan Kettering y ahora hace las actividades que ama.